508 related articles for article (PubMed ID: 25942479)
1. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
2. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Liu NA; Jiang H; Ben-Shlomo A; Wawrowsky K; Fan XM; Lin S; Melmed S
Proc Natl Acad Sci U S A; 2011 May; 108(20):8414-9. PubMed ID: 21536883
[TBL] [Abstract][Full Text] [Related]
3. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
4. E2F1-mediated human POMC expression in ectopic Cushing's syndrome.
Araki T; Liu NA; Tone Y; Cuevas-Ramos D; Heltsley R; Tone M; Melmed S
Endocr Relat Cancer; 2016 Nov; 23(11):857-870. PubMed ID: 27935805
[TBL] [Abstract][Full Text] [Related]
5. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
6. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
7. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
9. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
11. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
12. Role of NeuroD1 on the negative regulation of Pomc expression by glucocorticoid.
Parvin R; Saito-Hakoda A; Shimada H; Shimizu K; Noro E; Iwasaki Y; Fujiwara K; Yokoyama A; Sugawara A
PLoS One; 2017; 12(4):e0175435. PubMed ID: 28406939
[TBL] [Abstract][Full Text] [Related]
13. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.
Riebold M; Kozany C; Freiburger L; Sattler M; Buchfelder M; Hausch F; Stalla GK; Paez-Pereda M
Nat Med; 2015 Mar; 21(3):276-80. PubMed ID: 25665180
[TBL] [Abstract][Full Text] [Related]
14. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
[TBL] [Abstract][Full Text] [Related]
15. Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.
Hinojosa-Amaya JM; Lam-Chung CE; Cuevas-Ramos D
Front Endocrinol (Lausanne); 2021; 12():657382. PubMed ID: 33986726
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
17. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
18. A human ACTH-secreting corticotroph tumoroid model: Novel Human ACTH-Secreting Tumor Cell in vitro Model.
Zhang D; Hugo W; Redublo P; Miao H; Bergsneider M; Wang MB; Kim W; Yong WH; Heaney AP
EBioMedicine; 2021 Apr; 66():103294. PubMed ID: 33773184
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
Lu J; Chatain GP; Bugarini A; Wang X; Maric D; Walbridge S; Zhuang Z; Chittiboina P
J Clin Endocrinol Metab; 2017 Aug; 102(8):2825-2835. PubMed ID: 28505327
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Directed Therapeutic Targets in Cushing Disease.
Theodoropoulou M; Reincke M
J Clin Endocrinol Metab; 2019 Mar; 104(3):925-933. PubMed ID: 30535260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
